No-Go Zones for a Sandwich in a Divided Canadian City
In the Western Canadian town of Lloydminster, a business learned that it would break the law by making sandwiches at a supermarket and selling them a few blocks away. A ham and cheese, a BLT or a club, it didn't matter.
'If it involved meat, this is where it became an issue,' said Gerald Aalbers, the mayor of Lloydminster. 'Everything from a chub of bologna to a piece of roast beef.'
In Canada, meat and other food products cross provincial lines with great difficulty. Even after being inspected in one province, they must get federal certification before being shipped to another province — an insurmountable financial hurdle for many small businesses and part of a wider system of trade rules that Prime Minister Mark Carney says hobble the country's growth.
100 miles
Edmonton
Lloydminster
Alberta
Saskatchewan
Calgary
British
ColUmbia
Canada
United States
17
67 ST.
Township rd. 502
75 ave.
40 ave.
50 ave.
Yellowhead hwy.
Lloydminster
Saskatchewan
Alberta
12 st.
Canada
1 mile
By The New York Times
Ordinarily, any goods would move freely inside the same city. But because of a twist of history, Lloydminster happens to straddle the border between two provinces — Alberta and Saskatchewan — and must answer to two sets of regulations. A sandwich prepared on the Alberta side of Lloydminster could not be sold legally across the street in the Saskatchewan side without a federal seal of approval, and vice versa.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Cora Restaurants Enhances the Guest Experience Offering Online Reservations Powered by Libro
MONTREAL, July 31, 2025--(BUSINESS WIRE)--Cora restaurants, a Canadian leader in the breakfast scene for over 35 years, is proud to announce their partnership with Libro to offer an online reservation platform. Starting today, guests can now book their table in advance—quickly and easily. This move represents another step forward in enhancing the Cora customer experience, catering to today's demand for convenience, flexibility, and efficiency. The reservation platform is now accessible via the Cora website and directly through Google or Facebook. Guests can choose their preferred Cora location and time slot—all in just a few clicks. "We know our guests lead busy lives. With online reservations, they can now plan their visit with peace of mind, knowing their table is waiting for them when they arrive," says François Lamontagne, Vice President of Finance and Corporate Operations at Cora. The nationwide launch of the reservation platform is a strategic response to evolving consumer habits. Today's guests expect the same digital conveniences in dining as they do when booking a hotel or ordering groceries online. Libro's reservation platform reduces wait times during peak hours, including weekends, holidays, and busy mornings—making visits to Cora more enjoyable for all. "Cora is a Canadian icon, and we're thrilled to support their vision of exceptional hospitality," says Lorne Schwartz, President at Libro. About Franchises Cora Franchises Cora Inc. has over 100 restaurants from coast to coast, making it the largest breakfast restaurant chain in Canada. The company has been in business for more than thirty-five years. To learn more, visit About Libro Libro is one of North America's leading online guest experience solutions providing restaurants with an affordable, fully branded solution to fill tables, manage reservations, reduce no-shows, engage customers, and elevate the overall guest experience. For more information, visit View source version on Contacts Abby Chitester, VP Marketing at Libro abby@
Yahoo
13 minutes ago
- Yahoo
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
This Offering Will Not Dilute Quantum BioPharma Shareholders TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ('Quantum BioPharma'), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced that Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms – today announced the launch of its previously announced Regulation D 506(c) offering to raise up to US$5.0 million to fund growth and establish a path to a possible initial public offering. This will not impact or dilute Quantum BioPharma shareholders. Quantum BioPharma maintains an anti-dilution provision which ensures its ownership in Unbuzzd Wellness Inc. is 25% until unbuzzd reaches $1,000,000,000 (One Billion US Dollars) in valuation. Once Unbuzzd Wellness Inc. goes public, Quantum BioPharma will be able to access non-dilutive capital through its ownership. Unbuzzd has partnered with MZ Digital, a global leader in marketing, and Dealmaker, a leading online platform for raising capital to conduct the capital raise campaign. The Regulation D offering allows Unbuzzd to raise capital by selling and issuing securities to accredited investors without a cap on the amount raised. Investments can be made with traditional payments or with cryptocurrency payments: the latter through ALT5 Pay's digital payments platform. To learn more about the offering and invest, visit this link Unbuzzd Invest. John Duffy, CEO of Unbuzzd Wellness, stated, "This capital raise allows us to introduce investors to a new era in functional beverages aimed at supporting overall wellness after social occasions. unbuzzd is a refreshing, science-backed beverage that helps people feel more refreshed and alert after drinking. This offering will help us raise the necessary capital to support direct-to-consumer, distributor, and retail expansion plans.' Mr. Duffy has over twenty years of leadership experience in the beverage industry, including as former VP of Marketing Assets and VP of National Sales at Coca-Cola. Gerry David, Board Co-Chair and former CEO of Celsius Holdings with their bestselling energy drink Celsius Energy, added, "Together with our partners MZ Digital, a global leader in online marketing, and Dealmaker, a leading online platform for raising capital, we are excited to launch this offering to build our company and sales momentum, and position Unbuzzd for a future initial public offering." About Quantum BioPharma Ltd. Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ('Lucid'), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information on Quantum BioPharma, please visit About Unbuzzd Wellness Inc. Unbuzzd Wellness inc., a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day. Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration ("BAC"), restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. Key findings from the clinical trial include: Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was, on average for most participants, more than 40 percent faster within 30 minutes of consuming unbuzzd compared to control subjects. Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Participants felt more alert and made fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results. Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant. Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication. Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd. No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects. The full press release of the clinical trial can be found here. unbuzzd ready-to-mix powder sticks are available in 3-pack and 18-pack formats at unbuzzdTM is a registered trademark of Unbuzzd Wellness Inc. Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE. For more information on Unbuzzd Wellness Inc. please visit 18-pack, and 3-pack formats of the unbuzzd ready-to-mix powder sticks Forward-Looking Information Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such. Forward-looking information in this press release are based on certain assumptions and expected future events. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at and on the EDGAR section of the United States Securities and Exchange Commission's website at for a more complete discussion of such risk factors and their potential effects. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law. Contacts: Quantum BioPharma Saeed, Founder, CEO and Executive Co-Chairman of the BoardEmail: Zsaeed@ (833) 571-1811 Investor RelationsInvestor Relations: IR@ Inquiries: info@ A photo accompanying this announcement is available at in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
Flow Capital Announces a C$15.0M Investment in Common Wealth
TORONTO, ON, July 31, 2025 (GLOBE NEWSWIRE) -- Flow Capital Corp. (TSXV: FW) ('Flow Capital' or the 'Company') is pleased to announce a C$15.0 million senior secured note in Common Wealth Pension Services Inc. (dba 'Common Wealth'), a SaaS company serving the Canadian group retirement market, with a first tranche advance of C$4.0 million. Common Wealth offers a modern full-stack platform for group retirement plan administration. With a user-friendly interface and expert support, the platform empowers members to build long-term financial security, enables employers of all sizes to offer competitive retirement benefits, and equips advisors with tools to better serve clients and accelerate the growth of their group retirement practices. Flow Capital's investment will support Common Wealth in accelerating product innovation, expanding its customer base, and scaling operations, advancing the company's mission to make retirement security accessible to everyone in Canada. Growing technology companies seeking flexible, covenant-light, founder-friendly growth capital are encouraged to apply directly at About Common Wealth Common Wealth is driven by its mission to make retirement security accessible to everyone, currently serving over 1,100 employers across Canada, with especially rapid adoption among SMBs and the advisors who serve them. Common Wealth's vision is to provide its members with a 'retirement plan for life' that extends beyond the workplace, and to offer its advisor partners the best platform to power the growth of their businesses. Common Wealth's retirement technology platform has been awarded Pensions & Investments' global Innovation Award for Best Technology. For more information, please visit About Flow Capital Flow Capital Corp. is a publicly listed provider of flexible growth capital and alternative debt solutions dedicated to supporting high-growth companies. Since its inception in 2018, the company has provided financing to businesses in the US, the UK, and Canada, helping them achieve accelerated growth without the dilutive impact of equity financing or the complexities of traditional bank loans. Flow Capital focuses on revenue-generating, VC-backed, and founder-owned companies seeking growth capital to drive their continued expansion. Learn more at For further information, please contact: Flow Capital Corp. Alex BalutaChief Executive Officeralex@ 47 Colborne Street, Suite 303,Toronto, Ontario M5E 1P8 Forward-Looking Information and Statements Certain statements herein may be 'forward-looking' statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Flow or the industry to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether such results will be achieved. A number of factors could cause actual results to vary significantly from the results discussed in the forward-looking statements. These forward-looking statements reflect current assumptions and expectations regarding future events and operating performance and are made as of the date hereof and Flow assumes no obligation, except as required by law, to update any forward-looking statements to reflect new events or circumstances.
